B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for kids with hard-to-treat blood cancers
Disease control CompletedThis study tested whether adding a targeted drug called rituximab to standard chemotherapy helps children and teens with advanced B-cell lymphoma or leukemia. About 482 high-risk patients took part. The goal was to see if the combination improves how long they stay cancer-free wi…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
Can a rheumatoid arthritis drug tame CAR-T's worst side effects?
Symptom relief CompletedThis study tested whether anakinra, a drug used for rheumatoid arthritis, could prevent two serious side effects of CAR-T therapy: cytokine release syndrome (CRS) and nerve damage. 27 adults with B-cell lymphoma received anakinra alongside their CAR-T treatment. The goal was to s…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 15, 2026 19:07 UTC